Floatz logo

NEOMYCIN

Multiple Sclerosis, Relapsing-Remitting

Rush University Medical CentermixtureDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Multiple Sclerosis, Relapsing-Remitting cohort.

Asset / SponsorPhaseRating
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB
Ocrevus
Biocad
Phase 4BBB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Universitätsklinikum Hamburg-Eppendorf
Phase 4BBB

View all 50 →

Same molecule, other indications

NEOMYCIN is also rated in:

Surgical Site InfectionDormant
BBB
Indicative ·
72 / 100
View asset →
Rectum NeoplasmDormant
BB
Indicative ·
65 / 100
View asset →
Surgery--ComplicationsDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →